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Abstract
Background: Differences between an individual’s estimated epigenetic gestational age (EGA) and their actual
gestational age (GA) are defined as gestational age acceleration (GAA). GAA is associated with increased
birthweight and birth length. Whether these associations persist through childhood is yet to be investigated.
Methods: We examined the association between GAA and trajectories of height and weight from birth to 10 years
(n = 785) in a British birth cohort study, the Avon Longitudinal Study of Parents and Children (ALSPAC). EGA of
participants was estimated using DNA methylation data from cord blood using a recently developed prediction
model. GAA of participants, measured in weeks, was calculated as the residuals from a regression model of EGA on
actual GA. Analyses were performed using linear spline multilevel models and adjusted for maternal age, maternal
pre-pregnancy BMI, maternal smoking during pregnancy, and maternal education.
Results: In adjusted analyses, offspring with a one-week greater GAA were born on average 0.14 kg heavier (95%
confidence interval (CI) 0.09, 0.19) and 0.55 cm taller (95% CI 0.33, 0.78) at birth. These differences in weight
persisted up to approximately age 9 months but thereafter began to attenuate. From age 5 years onwards, the
association between GAA and weight reversed such that GAA was associated with lower weight and this
association strengthened with age (mean difference at age 10 years − 0.60 kg, 95% CI − 1.19, − 0.01). Differences in
height persisted only up to age 9months (mean difference at 9months 0.15 cm, 95% CI − 0.09, 0.39). From age 9months
to age 10 years, offspring with a one-week greater GAA were of comparable height with those with no GAA (mean
difference at age 10 years − 0.07 cm, 95% CI − 0.64, 0.50).
Conclusions: Gestational age acceleration is associated with increased birth weight and length and these differences
persist to age 9months. From age 5 years onwards, the association of GAA and weight reverses such that by age
10 years, greater GAA is associated with lower childhood weight. Further work is required to examine whether
the weight effects of GAA strengthen through adolescence and into early adulthood.
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Background
Epigenetic modifications refer to changes that do not
affect the underlying DNA base sequence but may affect
gene function and phenotypic expression [1]. DNA
methylation (DNAm) is one type of epigenetic mechan-
ism involving methylation of the cytosine nucleotide at
cytosine-phosphate-guanine (CpG) dinucleotide sites [1].
Environmental exposures such as tobacco smoking [2]
and alcohol consumption [3] are associated with altered
patterns of DNAm. DNAm levels also change with age
across some CpG sites. DNAm has therefore been used
to predict age in both children and adults [4, 5]. Differ-
ences between an individual’s epigenetic age and their
chronological age are defined as age acceleration (AA).
Positive AA (i.e. having a higher epigenetic than chrono-
logical age) is generally associated with a variety of adverse
health outcomes including obesity [6], Alzheimer’s disease
[7], cancer [8], lower physical and cognitive fitness [9],
and all-cause mortality [9].
Recently, the concept of epigenetic age was extended by
Bohlin et al. [10] and Knight et al. [11] using DNAm pat-
terns in cord blood to calculate epigenetic gestational age
(EGA), an estimation of gestational age at birth. Differences
between an individual’s EGA and their actual gestational
age (GA) are defined as gestational age acceleration (GAA).
In a recent study of the Avon Longitudinal Study of Parents
and Children (ALSPAC), GAA was associated with higher
birthweight and greater birth length [12]. Given that child-
hood height and weight are important indicators of overall
health and development [13–15], understanding whether
associations of GAA with growth measures persist through
childhood may provide insights into the potential impact of
GAA on later health in children.
In this study, we examine the association between GAA
and trajectories of weight and height from birth to age 10
years, using data derived from the Accessible Resource for
Integrated Epigenomic Studies (ARIES) project, a sub-
study of 1018 mother-offspring pairs from the ALSPAC.
Methods
Study participants
This study uses data collected in ALSPAC, a prospective
birth cohort study in southwest England [16, 17]. ALSPAC
recruited 14,541 pregnant women resident in Avon with
expected delivery dates between 1 April 1991 and 31 De-
cember 1992. Of these initial pregnancies, there were 14,
062 live births and 13,988 children who were alive at 1 year
of age. Follow-up has included parent and child completed
questionnaires, links to routine data, and clinic attendance.
Research clinics were held when the participants were ap-
proximately 7, 9, 10, 11, 13, 15, and 18 years old. The study
has been described elsewhere in detail [16, 17]. Ethical
approval for the study was obtained from the ALSPAC
Ethics and Law Committee and the Local Research Ethics
Committees. The study website contains details of all the
data that is available through a fully searchable data dic-
tionary and variable search tool (http://www.bristol.ac.uk/
alspac/researchers/our-data/). In a sub-study of 1018
ALSPAC mother-offspring pairs (the ARIES project) [18],
genome-wide DNA methylation profiling was performed
on offspring DNA samples at birth.
DNA methylation
DNA samples at birth were obtained from cord blood,
drawn from the umbilical cord upon delivery in accord-
ance with standard procedures. DNA methylation ana-
lysis of these samples was performed using the Illumina
Infinium HumanMethylation450K BeadChip assay [19].
All DNA methylation wet-lab and pre-processing ana-
lyses were performed at the University of Bristol as part
of the ARIES project. Following extraction, DNA was
bisulfite-converted using the Zymo EZ DNA Methyla-
tionTM kit (Zymo, Irvine, CA). The Illumina 450 K array
was used to quantify DNA methylation at over 485,000
CpG sites across the genome. The arrays were then
scanned using an Illumina iScan and initial quality re-
view was assessed using GenomeStudio. Samples then
underwent a number of further quality control pro-
cesses. For each sample, the estimated level of DNA
methylation at each CpG site was reported as a beta
value (β), ranging from 0 (no cytosine methylation) to 1
(complete cytosine methylation) [18].
Epigenetic gestational age and gestational age
acceleration
EGA of participants was estimated from DNA methyla-
tion data using the Bohlin et al. epigenetic clock model
[10]. This model uses 96 CpG sites to estimate GA at
birth from cord blood DNA methylation. The Bohlin
et al. model was used here instead of the Knight et al.
model [11] due to its stronger correlation with GA in
ARIES (R = 0.65 compared with R = 0.37) [12, 20]. GA of
subjects was gathered in ALSPAC from clinical records
and was measured from last menstrual period (LMP) for
the majority of subjects, although this measure was up-
dated for some individuals following a dating ultrasound.
GAA of participants, measured in weeks, was calculated
as the residuals from a regression model of EGA on
actual GA [12]. It is not known which method of GA
measurement was used for different individuals; how-
ever, the proportion of subjects in which GA was up-
dated from ultrasound is likely to be small as this
was not common practice at the time of measurement
[12]. A positive GAA value corresponds to an EGA
which is greater than actual GA. Conversely, a nega-
tive GAA value corresponds to an EGA which is less
than actual GA.
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Measurement of height and weight
Birthweight, birth length, height, and weight were col-
lected from several sources from birth to 10 years, in-
cluding measurement by trained ALPSAC staff shortly
after birth, research clinics, routine child health clinics,
links to health visitor records, and parent-reported mea-
sures from questionnaires. Full details of measurement
of height and weight are included in Additional file 1.
Statistical analyses
We used multilevel models to examine the association
between GAA and trajectories of height and weight from
birth to age 10 years. Multilevel models have been used
previously to model trajectories for risk factors in child-
hood [21–23]. Multilevel models estimate both average
and individual-specific trajectories whilst accounting for
the change in scale and variance of growth measures
over time and the non-independence of repeated mea-
sures within individuals [24]. Multilevel models also
account for differences in the number and timing of
measurements between individuals, allowing all available
data from eligible participants to be included under a
Missing at Random (MAR) assumption (i.e. that the
missingness is not specifically related to participants’
height/weight), thereby maximising the number of in-
cluded participants and minimising selection bias.
Height/weight trajectories were previously modelled [25]
and estimated using random effects linear spline multilevel
models (two levels: measurement occasion and individual).
Linear spline models divide the growth trajectory into
periods in which change is approximately linear [25]. With
random intercept and random effects for each spline (slope
term), individual trajectories are flexible about the mean
trend. For length/height growth, knots were placed at 3
months, 12months, and 36months, resulting in four
periods of change; birth to 3months, 3 to 12months, 12 to
36months, and 36 to 120months. For weight change, an
additional knot was placed at 84months, resulting in five
periods of change; birth to 3months, 3 to 12months, 12 to
36months, 36 to 84months, and 84 to 120months. Trajec-
tories were modelled separately for males and females, and
only up to age 10 years due to variability in age at puberty
onset which would require knot points to be placed at dif-
ferent ages for each individual. Further details are included
in Additional file 1.
The associations between GAA and the height/weight
trajectories were modelled by including interaction terms
between GAA and the intercept (birth length/weight) and
slopes (rate of height/weight growth in each linear spline
period). We performed unadjusted and confounder-
adjusted analyses. We considered maternal pre-pregnancy
BMI, maternal age, maternal education, and maternal
smoking during pregnancy as potential confounders (all
measured by mother-completed questionnaires; details in
Additional file 1). Covariates were included as interactions
between each covariate and the intercept and linear slopes
in the multilevel models. All participants with a measure
of GAA, at least one measure of height/weight from birth
to 10 years and complete data on all covariates were in-
cluded, leading to a total sample of 785 (398 females and
387 males) included in analyses. All analyses were con-
ducted using the statistical packages Stata version 15.1
[26], MLwiN version 3.01 [27], and the Stata command
‘runmlwin’ [28].
Sensitivity analyses
We performed sensitivity analyses, examining the associ-
ation of GAA with observed measures of height/weight at
birth, age 3 years, and age 10 years using linear regression
to examine the suitability of our modelling strategy. We
also compared characteristics of participants who were in-
cluded in our analysis versus participants who were ex-
cluded due to missing data on exposure, outcome, or
confounders. Additionally, we examined the association of
GAA and offspring BMI (as calculated from observed mea-
sures of height and weight) at age 10 years using linear re-
gression, for both males and females, with adjustment for
the same potential confounders as in our main analyses.
Results
Study participants
Characteristics of participants included in our analysis are
shown in Table 1. Mothers of offspring included in the ana-
lysis (n = 785) were likely to be older, be married, have
attained a higher level of education, and were less to likely
to smoke during pregnancy relative to the rest of the
ALSPAC study population excluded due to missing data on
exposure, outcome, or confounders (n = 13,446) (Additional
file 1: Table S2). Included participants had a total of 9515
height and weight measurements with a median of 13 mea-
sures per individual (interquartile range (IQR) 9 to 19).
Weight
In the unadjusted analysis (Table 2), a one-week greater
GAA was associated with 0.15 kg higher birth weight (95%
confidence interval (CI) 0.09, 0.20). Offspring with a one-
week greater GAA continued to be heavier than those with
no GAA up to 7 years (mean difference 0.12 kg, 95% CI −
0.25, 0.49), albeit with confidence intervals that spanned the
null value from age 1 year onwards. From age 8 years, a
one-week greater GAA was associated with lower weight
although this difference spanned the null value throughout
(mean difference at age 10–0.26 kg, 95% CI − 0.86, 0.35). In
the confounder-adjusted analysis (Table 3), associations
were similar but with greater evidence for a reversal of the
association of GAA and weight from positive to negative
across childhood. Weight differences for a one-week greater
GAA were present at birth, persisted up to age 4 years
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(mean difference 0.02 kg, 95% CI − 0.16, 0.21) but with con-
fidence intervals that spanned the null from 9months.
From age 5 years, the association reversed such that GAA
was associated with lower weight and this association
strengthened with age (mean difference at age 10 –0.60 kg,
95% CI − 1.19, − 0.01). A one-week greater GAA was asso-
ciated with a slower rate of weight growth from birth on-
wards, albeit with confidence intervals that spanned the
null (Additional file 1: Table S4). This explains the attenu-
ation of differences in weight by GAA at age 9months and
eventual reversal of the association between GAA and
weight at age 5 years.
Length/height
In the unadjusted analysis (Table 2), a one-week greater
GAA was associated with 0.55 cm greater birth length
(95% CI 0.33, 0.78). Differences in height for a one-
week greater GAA diminished with age and confidence
intervals spanned the null value from age 9 months
onwards. In the confounder-adjusted analysis (Table 3),
findings were similar but there was some evidence of a
reversal of the association of GAA and height from age
8 years, albeit with confidence intervals that spanned
Table 1 Characteristics of the study sample (n = 785)
n % of study sample
Sex of child
Male 387 49.3
Female 398 50.7
Maternal age (years)
35+ 107 13.6
25–34 586 74.7
15–24 92 11.7
Maternal education*
Degree or above 160 20.4
A level 242 30.8
O level 258 32.9
Less than O level 125 15.9
Maternal smoking during pregnancy
Never 477 60.8
Ever 308 39.2
Maternal pre-pregnancy BMI
Under/normal weight 637 81.2
Overweight 111 14.1
Obese 37 4.7
Maternal marital status during pregnancy**
Never married 93 11.9
Married 650 83.1
Divorced/separated/widowed 39 5.0
Parity**
0 651 84.3
1 93 12.1
2+ 28 3.6
Median IQR***
Gestational age at birth (weeks) 40 39, 41
*O level (ordinary level: exams taken in different subjects usually at age 15–16
at the completion of legally required school attendance, equivalent to today’s
UK General Certificate of Secondary Education), A level (advanced level: exams
taken in different subjects usually at age 18), or university degree or above
**Denominator less than 785 as data not required for inclusion in the
study population
***Interquartile range
Table 2 Unadjusted association of gestational age acceleration
(GAA) with predicted offspring weight and length/height at
multiple ages (n = 785)
Mean (SD)
[Offspring
with no GAA]
Mean difference (95% CI)
per week increase in GAA
Weight (kg)
Birth 3.38 (0.31) 0.15 (0.09, 0.20)
3 months 6.01 (0.62) 0.10 (0.01, 0.18)
6 months 7.34 (0.72) 0.10 (0.02, 0.18)
9 months 8.67 (0.88) 0.09 (0.0002, 0.19)
1 year 9.99 (1.07) 0.09 (− 0.03, 0.21)
3 years 14.62 (1.53) 0.09 (− 0.08, 0.26)
4 years 16.91 (1.93) 0.10 (− 0.09, 0.28)
5 years 19.21 (2.48) 0.10 (− 0.12, 0.33)
6 years 21.51 (3.11) 0.11 (− 0.18, 0.41)
7 years 23.80 (3.78) 0.12 (− 0.25, 0.49)
8 years 27.71 (4.76) − 0.006 (− 0.39, 0.38)
9 years 31.62 (5.93) − 0.13 (− 0.61, 0.34)
10 years 35.53 (7.20) − 0.26 (− 0.86, 0.35)
Height (cm)
Birth 50.17 (1.33) 0.55 (0.33, 0.78)
3 months 61.07 (1.50) 0.34 (0.08, 0.60)
6 months 65.86 (1.71) 0.24 (0.01, 0.46)
9 months 70.65 (2.01) 0.13 (− 0.11, 0.37)
1 year 75.44 (2.37) 0.03 (− 0.27, 0.33)
3 years 95.71 (3.33) 0.15 (− 0.24, 0.55)
4 years 102.25 (3.56) 0.14 (− 0.25, 0.52)
5 years 108.81 (3.83) 0.12 (− 0.27, 0.51)
6 years 115.36 (4.13) 0.11 (− 0.30, 0.51)
7 years 121.91 (4.46) 0.09 (− 0.34, 0.52)
8 years 128.47 (4.82) 0.07 (− 0.40, 0.55)
9 years 135.02 (5.19) 0.06 (− 0.46, 0.57)
10 years 141.57 (5.57) 0.04 (− 0.52, 0.61)
Offspring height and weight values are predicted from the multilevel models.
There was no evidence of a gender interaction for the association between
GAA and height/weight trajectories and thus, all values presented are for
females. Reference category is females with no GAA (no difference between
EGA and actual gestational age). Weight is in kilogrammes, length/height is
in centimetres
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the null value (mean difference at age 10–0.07 cm, 95%
CI − 0.64, 0.50). A one-week greater GAA was generally
associated with a slower rate of height growth from
birth onwards, albeit with confidence intervals that
spanned the null (Additional file 1: Table S4). This ex-
plains the attenuation of differences in height by GAA
at age 9 months and eventual reversal of the association
between GAA and height from age 8 years.
Sensitivity analysis
Examination of the association of GAA with observed
measures of weight and height (rather than predicted
measures from multilevel models) at birth, age 3 years,
and age 10 years using linear regression produced similar
results, providing reassurance that our modelling strat-
egy was appropriate (Additional file 1: Table S3). In the
linear regression analysis of GAA and offspring BMI at
age 10 years, a one-week greater GAA was associated
with a lower BMI at age 10 years in females (mean log
BMI 2.84, mean difference − 0.03 per week greater GAA,
95% CI − 0.06, − 0.0006). There was some evidence that
greater GAA was associated with reduced BMI at age
10 years in males although confidence intervals spanned
the null (mean log BMI 2.83, mean difference − 0.007 per
week greater GAA, 95% CI − 0.04, 0.02).
Discussion
Summary
Using cord blood DNAm at birth to calculate EGA, we
examined the association between GAA and trajectories
of childhood weight and height from birth to 10 years in
the ARIES subsample of ALSPAC. Our findings showed
that GAA was associated with higher birthweight and
birth length as demonstrated previously [12] and that
this difference persisted up to approximately 9 months
of age. From age 9 months onwards, these differences
continued to attenuate and eventually reversed for
weight, resulting in approximately 0.6 kg lower weight at
age 10 years per week greater GAA.
Previous research
To our knowledge, this is the first study to examine the
association of GAA with measures of weight and height
beyond birth and across childhood. A previous study
examining DNA methylation patterns in cord blood DNA
found that DNA methylation levels in only 1 of their stud-
ied genes was associated with body size at age 9 years [29];
a finding which contrasts slightly with the association of
GAA and lower weight from age 5 years found here which
strengthened with age. A study of AA also conducted in
the ARIES subsample of ALSPAC found that AA at age 7
years was positively associated with height, but not with
weight, from 7 to 17 years [30]. The same study found that
AA at birth was associated with a higher fat mass from
birth to age 17 years but found no evidence of an associ-
ation between AA and birthweight or length, in contrast
to the association here between GAA and birthweight/
length. However, it should be noted that epigenetic
age/AA are uncorrelated with gestational age at birth
[31] and the CpG sites used to measure GAA [10] differ
substantially from those used in the Horvath model [4]
to measure AA. These findings indicate that AA and GAA
are largely independent constructs, offering an explanation
Table 3 Confounder-adjusted association of gestational age
acceleration (GAA) with predicted offspring weight and length/
height at multiple ages (n = 785)
Mean (SD)
[Offspring
with no GAA]
Mean difference (95% CI)
per week increase in GAA
Weight (kg)
Birth 3.44 (0.30) 0.14 (0.09, 0.19)
3 months 5.98 (0.61) 0.10 (0.02, 0.19)
6 months 7.29 (0.71) 0.09 (0.01, 0.18)
9 months 8.61 (0.87) 0.09 (− 0.01, 0.18)
1 year 9.92 (1.06) 0.08 (− 0.04, 0.20)
3 years 14.44 (1.50) 0.05 (− 0.12, 0.23)
4 years 16.70 (1.87) 0.02 (− 0.16, 0.21)
5 years 18.95 (2.39) − 0.008 (− 0.23, 0.22)
6 years 21.21 (2.98) − 0.04 (− 0.33, 0.25)
7 years 23.47 (3.61) − 0.07 (− 0.43, 0.29)
8 years 27.26 (4.52) − 0.25 (− 0.63, 0.13)
9 years 31.05 (5.63) − 0.43 (− 0.89, 0.04)
10 years 34.85 (6.83) − 0.60 (− 1.19, − 0.01)
Height (cm)
Birth 50.41 (1.34) 0.55 (0.33, 0.78)
3 months 60.96 (1.50) 0.35 (0.09, 0.62)
6 months 65.69 (1.71) 0.25 (0.02, 0.48)
9 months 70.41 (2.01) 0.15 (− 0.09, 0.39)
1 year 75.13 (2.37) 0.05 (− 0.26, 0.35)
3 years 95.24 (3.29) 0.11 (− 0.28, 0.50)
4 years 101.78 (3.51) 0.09 (− 0.30, 0.47)
5 years 108.32 (3.78) 0.06 (− 0.33, 0.45)
6 years 114.85 (4.08) 0.03 (− 0.37, 0.44)
7 years 121.39 (4.41) 0.008 (− 0.43, 0.44)
8 years 127.92 (4.76) − 0.02 (− 0.49, 0.46)
9 years 134.46 (5.13) − 0.04 (− 0.56, 0.47)
10 years 140.99 (5.51) − 0.07 (− 0.64, 0.50)
Offspring height and weight values are predicted from the multilevel models,
based on models adjusted for maternal age, maternal smoking during
pregnancy, maternal education, and maternal pre-pregnancy BMI. There was
no evidence of a gender interaction for the association between GAA and
height/weight trajectories and thus, all values presented are for females.
Reference category is females with no GAA (no difference between EGA and
actual gestational age). Weight is in kilogrammes, length/height is
in centimetres
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for the disparity seen in associations of GAA and AA with
birth/childhood anthropometric outcomes.
Potential implications
Our results indicate that GAA is not strongly associated
with increased childhood weight and height for most of
childhood but that by age 10 years, GAA is associated
with lower weight. The attenuation of the association be-
tween GAA and body size after birth could be due to
the reversibility of epigenetic changes i.e. methylation
patterns are not fixed and may be modified. The process
of DNAm reversibility with age has been observed previ-
ously, such as the effect of maternal smoking during
pregnancy on offspring DNA methylation levels which
were found to have reverted at many CpG sites by age 7
years [32]. The attenuation of the association between
GAA and childhood height/weight may therefore be
driven by a developmental effect whereby differences in
DNAm at birth among offspring with greater GAA are
resolved with increasing age. Our findings also suggest
that children with greater GAA have higher birthweight
but experience a slower rate of growth during childhood.
This slower rate of growth during childhood may be
driven by biological compensatory mechanisms (such as
catch-down growth in childhood due to higher birth-
weight). However, our finding that GAA was associated
with lower BMI in females and males at age 10 may also
indicate that the reversal of the association of GAA with
weight across childhood is driven by associations with
other health factors such as physical activity and general
health, due to their lower levels of adiposity at age 10.
Further work is therefore required to examine associa-
tions of GAA with other health indicators such as lean
mass and physical activity, and additionally to examine
associations of GAA with anthropometry and health fac-
tors beyond age 10 years to better understand the impli-
cations of GAA on child health in the long term. In
particular, analysis of GAA with weight and BMI beyond
age 10 years is required to examine whether the associ-
ation of GAA with lower weight and BMI at age 10
years strengthens with age.
The Bohlin et al. epigenetic clock model measures
DNA methylation levels in cord blood only and there-
fore does not examine DNA methylation changes in
other tissues at birth. As tissue-specific age acceleration
associations have been observed previously, such as the
association between AA in liver cells and obesity [6], in-
vestigation of gestational age-related DNA methylation
patterns in foetal tissues other than cord blood may also
provide important insights.
Strengths and limitations
There are several strengths to our study including the
use of repeated measures of height and weight from
birth to 10 years and the use of multilevel models allow-
ing all individuals with at least one measure of height
and weight to be included in analyses, thereby reducing
the possibility of selection bias. The Bohlin et al. [10]
epigenetic clock model transferred well to the ARIES
study population, achieving a high correlation between
EGA and actual GA (R = 0.65) [20]. Limitations include
estimation of GA from LMP rather than the ‘gold stand-
ard’ of dating ultrasound, which may have implications
for our estimation of EGA, as the Bohlin et al. model
produces more accurate EGA estimates in cohorts in
which GA has been measured from ultrasound [10].
Height and weight data in ALSPAC were obtained from
a range of sources with varying degrees of reliability;
parent-reported measures from questionnaires will likely
have less accuracy than research clinic measurements
following strict methodology. However, our models have
aimed to minimise this by accounting for differential
measurement error across measurement sources (see
Additional file 1 for handling of clinic and parent-
reported measurements). Participants included in our
analysis were more advantaged than those excluded due
to missing exposure, outcome, or confounder data,
introducing the possibility of selection bias and reducing
generalisability of findings. The Bohlin et al. model was
developed using the HumanMethylation450K BeadChip
assay [19] which has some recognised technical biases
and only profiles 1.7% of CpG sites in the genome. The
assay may therefore have failed to identify some CpGs
that are differentially methylated in newborns at birth.
The model also applies solely to DNAm in cord blood,
which may not be the optimal tissue for relating EGA
and physical development.
Conclusions
Gestational age acceleration is associated with increased
birthweight and length with differences persisting to age
9 months. From age 5 years onwards, the association of
GAA and weight reverses such that by age 10 years,
greater GAA is associated with lower weight. Further
work is required to examine whether the weight effects
of GAA strengthen through adolescence and into early
adulthood.
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